V Craig Jordan

Summary

Affiliation: Georgetown University
Country: USA

Publications

  1. ncbi The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities
    V Craig Jordan
    Lomhardi Comprehensive Cancer Center, Georgetown University, Washington, BC 20057, USA
    Breast 20:S1-11. 2011
  2. ncbi The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
    Philipp Y Maximov
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Rd NW, Research Building, Suite E204A, Washington, DC 20057, USA
    Curr Clin Pharmacol 8:135-55. 2013
  3. ncbi Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis
    V Craig Jordan
    Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 4:633-7. 2011
  4. ncbi Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Eur J Cancer 48:3488-98. 2012
  5. ncbi Progress in endocrine approaches to the treatment and prevention of breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States
    Maturitas 70:315-21. 2011

Collaborators

  • Philipp Y Maximov
  • Ping Fan
  • Ifeyinwa Obiorah
  • Theresa M Lee
  • Bassem Haddad
  • Helen R Kim
  • Dionyssia Clagett
  • Russell E McDaniel

Detail Information

Publications5

  1. ncbi The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities
    V Craig Jordan
    Lomhardi Comprehensive Cancer Center, Georgetown University, Washington, BC 20057, USA
    Breast 20:S1-11. 2011
    ....
  2. ncbi The Discovery and Development of Selective Estrogen Receptor Modulators (SERMs) for Clinical Practice
    Philipp Y Maximov
    Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3970 Reservoir Rd NW, Research Building, Suite E204A, Washington, DC 20057, USA
    Curr Clin Pharmacol 8:135-55. 2013
    ..In this article, we describe the discovery and development of the group of medicines called SERMs. The newer SERMs in late development: ospemifene, lasofoxifene, bazedoxifene, are arzoxifene are described in detail...
  3. ncbi Paradoxical clinical effect of estrogen on breast cancer risk: a "new" biology of estrogen-induced apoptosis
    V Craig Jordan
    Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA
    Cancer Prev Res (Phila) 4:633-7. 2011
    ..Cell populations emerge with a vulnerability, as estrogen is no longer a survival signal but is an apoptotic trigger. The antitumor effect of ERT in estrogen-deprived postmenopausal women is consistent with laboratory models...
  4. ncbi Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines
    Ping Fan
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road NW, Washington, DC 20057, USA
    Eur J Cancer 48:3488-98. 2012
    ..A specific c-Src inhibitor, 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-d]pyrinidine (PP2), was utilised to block c-Src activity to identify targeted vulnerabilities affected by ER and HER2 in a panel of breast cancer cell lines...
  5. ncbi Progress in endocrine approaches to the treatment and prevention of breast cancer
    Ifeyinwa Obiorah
    Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States
    Maturitas 70:315-21. 2011
    ..This review outlines the current strategies employed in the use of endocrine therapy in the management and prevention of breast cancer...